ClinicalTrials.gg
CompletedNCT03734029Updated Sep 28, 2026Results posted

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

A Phase 3 interventional study of Trastuzumab deruxtecan (DS-8201a) and Capecitabine in Breast Cancer, sponsored by Daiichi Sankyo. Completed at 208 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Daiichi Sankyo · Phase 3, Interventional, and Treatment

Updated Sep 28, 2026Now CompletedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
557
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms — 31 open to participants now, 45 under way, 8 of them phase 3. trastuzumab deruxtecan · Breast Neoplasms.

Enrollment
6th of 58
557 · median 139
Started
2018
with 5 others
Phase 3
12 of 58
3 open now
Registered
8th of 58
by date
Lead sponsor
9 of 58
Daiichi Sankyo

Among the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, this one is the 6th largest by enrollment, is one of 6 that started in 2018, is one of 12 in phase 3, and was the 8th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

31 of the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 31 open studies →

About trastuzumab deruxtecan

trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

This study will compare DS-8201a to physician choice standard treatment.

Participants must have HER2-low breast cancer that has been treated before.

Participants' cancer:

  • Cannot be removed by an operation
  • Has spread to other parts of the body
Read the detailed description

This is a randomized, 2-arm, Phase 3, open-label, multicenter study to compare the safety and efficacy of trastuzumab deruxtecan versus the physician's choice (2:1) in HER2-low, unresectable and/or metastatic breast cancer participants.

The Sponsor proposes to define a new HER2-low population in this trial including tumors with IHC 1+ and IHC 2+/ISH- HER2 expression.

03

Conditions studied

  • Breast Cancer

Keywords

  • Anti-HER2-Antibody Drug Conjugate (ADC)
  • Unresectable or Metastatic
  • Human epidermal growth factor receptor 2 (HER2)-low
  • DESTINY - Breast 04
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is the age of majority in their country
  • Has documented breast cancer that:

    1. Is unresectable or
    2. Has low- expression defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested)
    3. Is HR-positive or HR-negative
    4. Has progressed on, and would no longer benefit from, endocrine therapy
    5. Has been treated with 1 to 2 /adjuvant in the recurrent or metastatic setting
    6. Was never previously HER2-positive (ICH 3+ or ISH+) on prior pathology testing (per American Society of Clinical Oncology-College of American Pathologists [ASCO-CAP] guidelines)
  • Has documented radiologic progression (during or after most recent treatment)
  • Has adequate available or is wiling to provide fresh biopsies prior to randomization for:

    1. assessment of HER2 status
    2. assessment of post-treatment status
  • Has at least 1 per 1.1
  • Has protocol-defined adequate cardiac, bone marrow, renal, hepatic and blood clotting functions
  • Male and female participants of reproductive/, agrees to follow instructions for method(s) of and agrees to avoid preserving ova or sperm for at least 4.5 months after treatment (or longer, per locally approved labels)

Exclusion criteria

Exclusion Criteria:

  • Is ineligible for all options in the physician's choice arm
  • Has breast cancer ever assessed with high- expression
  • Has previously been treated with any anti-HER2 therapy, including an antibody drug conjugate
  • Has uncontrolled or significant cardiovascular disease
  • Has spinal cord compression or clinically active central nervous system
  • Has history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required , has current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
  • Has any medical history or condition that per protocol or in the opinion of the investigator is inappropriate for the study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
557 participants (actual)

Study arms

  • Experimental
    Trastuzumab deruxtecan

    HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to DS8201a

    Drug: Trastuzumab deruxtecan (DS-8201a)

  • Active comparator
    Physician's Choice

    HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to Physician's choice from the following options: * Capecitabine * Eribulin * Gemcitabine * Paclitaxel * Nab-paclitaxel

    Drug: Capecitabine · Drug: Eribulin · Drug: Gemcitabine · Drug: Paclitaxel · Drug: Nab-paclitaxel

Interventions

  • DS-8201a is a lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously

    Also known as: DS-8201a

  • Administered according to label, as one option for Physician's Choice (determined before randomization)

  • Administered according to label, as one option for Physician's Choice (determined before randomization)

  • Administered according to label, as one option for Physician's Choice (determined before randomization)

  • Administered according to label, as one option for Physician's Choice (determined before randomization)

  • Administered according to label, as one option for Physician's Choice (determined before randomization)

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer

    Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on blinded independent central review (BICR) in the hormone receptor-positive cohort according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.

    Time frame: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years

Secondary outcomes

  1. Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-low Breast Cancer (All Patients) Regardless of Hormone Receptor Status

    Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on blinded independent central review (BICR) according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.

    Time frame: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years

  2. Progression-free Survival Based on Investigator Assessment in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer

    Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on investigator assessment in the hormone receptor-positive cohort according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.

    Time frame: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years

  3. Progression-free Survival Based on Investigator Assessment in Participants With HER2-low Breast Cancer (All Patients)

    Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on investigator assessment according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.

    Time frame: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years

  4. Overall Survival (OS) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer

    Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there was no death reported for a participant before the data cutoff for OS analysis, OS was censored at the last contact date at which the participant was known to be alive.

    Time frame: From the date of randomization up to the date of death due to any cause, up to approximately 3 years

  5. Number of Overall Survival Events (Deaths)

    Time frame: From the date of randomization up to the date of death due to any cause, up to approximately 3 years

  6. Overall Survival (OS) in All Patients

    Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there was no death reported for a participant before the data cutoff for OS analysis, OS was censored at the last contact date at which the participant was known to be alive.

    Time frame: From the date of randomization up to the date of death due to any cause, up to approximately 3 years

  7. Best Overall Response and Confirmed Objective Response Rate (ORR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer

    Best overall response rate and confirmed objective response rate (ORR) were assessed by blinded independent central review (BICR) and investigator assessment. Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Confirmed ORR was defined as the number of participants with complete and partial responses and confirmed by a second assessment.

    Time frame: From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years

  8. Best Overall Response and Confirmed Objective Response Rate (ORR) in Participants With HER2-low Breast Cancer (All Patients)

    Best overall response rate and confirmed objective response rate (ORR) were assessed by blinded independent central review (BICR) and investigator assessment. Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Confirmed ORR was defined as the number of participants with complete and partial responses and confirmed by a second assessment.

    Time frame: From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years

  9. Duration of Response in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer

    Duration of Response (DoR) is defined as the date of the first documented objective response (complete response \[CR\] or partial response \[PR\]) to the first documented disease progression or death, whichever occurs first. DoR was based on blinded independent central review (BICR) and investigator assessment. Median was from Kaplan-Meier estimate. Confidence interval for median was computed using the Brookmeyer-Crowley method.

    Time frame: From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years

  10. Duration of Response in Participants With HER2-low Breast Cancer (All Patients)

    Duration of Response (DoR) is defined as the date of the first documented objective response (complete response \[CR\] or partial response \[PR\]) to the first documented disease progression or death, whichever occurs first. DoR was based on blinded independent central review (BICR) and investigator assessment. Median was from Kaplan-Meier estimate. Confidence interval for median was computed using the Brookmeyer-Crowley method.

    Time frame: From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years

Other outcomes

  1. All-Cause Mortality

    All-cause mortality is defined as all anticipated and unanticipated deaths due to any cause, with the number and frequency of such events by arm or comparison group of the clinical study.

    Time frame: From the date of randomization up to the date of death due to any cause, up to approximately 3 years

07

Results

Posted Jun 15, 2023

Participant flow

A total of 557 participants were enrolled and randomized to treatment at 161 study sites in the United States (27 study sites), Japan (18 sites), France (16 sites), China (15 sites), Italy (13 sites), Spain (12 sites), Greece (8 sites), Portugal (8 sites), Republic of Korea (8 sites), Israel (6 sites), Switzerland (6 sites), Austria (4 sites), Belgium (4 sites), Russia (3 sites), Sweden (3 sites), Taiwan (3 sites), Unted Kingdom (3 sites), Canada (2 sites), and Hungary (2 sites).

Participant flow — Overall Study
MilestoneTrastuzumab Deruxtecan (T-DXd)Physician's Choice
Started373184
Full analysis set (all randomized patients)373184
Safety analysis set (all randomized patients who received at least 1 dose of study treatment)371172
Completed583
Not completed315181
Withdrew: Progressive disease as per recist v1.1220130
Withdrew: Adverse event6014
Withdrew: Withdrawal by subject1211
Withdrew: Clinical progression by investigator108
Withdrew: Death52
Withdrew: Physician decision43
Withdrew: Other20
Withdrew: Lost to follow-up01
Withdrew: Randomized, but not treated212

Outcome measures

PrimaryProgression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer

Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on blinded independent central review (BICR) in the hormone receptor-positive cohort according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.

Time frame:
From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
Reported as:
Median · months
Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
monthsTrastuzumab Deruxtecan (T-DXd)Physician's Choice
Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer10.1 (9.5 to 11.5)5.4 (4.4 to 7.1)
Statistical analysis
  • Trastuzumab Deruxtecan (T-DXd) vs Physician's Choice · Log Rank · p = <0.0001 (Two-sided p-value from stratified log-rank test, Hazard ratio and 95% CI from stratified Cox proportional hazards model using stratification factors: HER2 status, number of prior lines of chemotherapy, hormone Receptor/CDK status, as defined by IXRS.) · Cox proportional hazard: 0.5085 · 95% CI 0.4012 to 0.6444
SecondaryProgression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-low Breast Cancer (All Patients) Regardless of Hormone Receptor Status

Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on blinded independent central review (BICR) according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.

Time frame:
From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
Reported as:
Median · months
Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-low Breast Cancer (All Patients) Regardless of Hormone Receptor Status
monthsTrastuzumab Deruxtecan (T-DXd)Physician's Choice
Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-low Breast Cancer (All Patients) Regardless of Hormone Receptor Status9.9 (9.0 to 11.3)5.1 (4.2 to 6.8)
SecondaryProgression-free Survival Based on Investigator Assessment in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer

Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on investigator assessment in the hormone receptor-positive cohort according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.

Time frame:
From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
Reported as:
Median · months
Progression-free Survival Based on Investigator Assessment in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
monthsTrastuzumab Deruxtecan (T-DXd)Physician's Choice
Progression-free Survival Based on Investigator Assessment in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer9.6 (8.4 to 10.0)4.2 (3.4 to 4.9)
SecondaryProgression-free Survival Based on Investigator Assessment in Participants With HER2-low Breast Cancer (All Patients)

Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on investigator assessment according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.

Time frame:
From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
Reported as:
Median · months
Progression-free Survival Based on Investigator Assessment in Participants With HER2-low Breast Cancer (All Patients)
monthsTrastuzumab Deruxtecan (T-DXd)Physician's Choice
Progression-free Survival Based on Investigator Assessment in Participants With HER2-low Breast Cancer (All Patients)8.8 (8.3 to 9.8)4.2 (3.0 to 4.5)
SecondaryOverall Survival (OS) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer

Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there was no death reported for a participant before the data cutoff for OS analysis, OS was censored at the last contact date at which the participant was known to be alive.

Time frame:
From the date of randomization up to the date of death due to any cause, up to approximately 3 years
Reported as:
Median · months
Overall Survival (OS) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
monthsTrastuzumab Deruxtecan (T-DXd)Physician's Choice
Overall Survival (OS) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer23.9 (20.8 to 24.8)17.5 (15.2 to 22.4)
SecondaryNumber of Overall Survival Events (Deaths)
Time frame:
From the date of randomization up to the date of death due to any cause, up to approximately 3 years
Reported as:
Number · events (deaths)
Number of Overall Survival Events (Deaths)
events (deaths)Trastuzumab Deruxtecan (T-DXd)Physician's Choice
Number of Overall Survival Events (Deaths)14990
SecondaryOverall Survival (OS) in All Patients

Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there was no death reported for a participant before the data cutoff for OS analysis, OS was censored at the last contact date at which the participant was known to be alive.

Time frame:
From the date of randomization up to the date of death due to any cause, up to approximately 3 years
Reported as:
Median · months
Overall Survival (OS) in All Patients
monthsTrastuzumab Deruxtecan (T-DXd)Physician's Choice
Overall Survival (OS) in All Patients23.4 (20.0 to 24.8)16.8 (14.5 to 20.0)
SecondaryBest Overall Response and Confirmed Objective Response Rate (ORR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer

Best overall response rate and confirmed objective response rate (ORR) were assessed by blinded independent central review (BICR) and investigator assessment. Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Confirmed ORR was defined as the number of participants with complete and partial responses and confirmed by a second assessment.

Time frame:
From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years
Reported as:
Count of participants · Participants
Best Overall Response and Confirmed Objective Response Rate (ORR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
ParticipantsTrastuzumab Deruxtecan (T-DXd)Physician's Choice
BICR: Complete response121
BICR: Partial response16426
BICR: Stable disease11581
BICR: Progressive disease2634
BICR: Not evaluable1421
Investigator: Complete response50
Investigator: Partial response16330
Investigator: Stable disease12480
Investigator: Progressive disease2834
Investigator: Not evaluable1119
BICR: Confirmed Objective response rate17527
Investigator: Confirmed Objective response rate16830
SecondaryBest Overall Response and Confirmed Objective Response Rate (ORR) in Participants With HER2-low Breast Cancer (All Patients)

Best overall response rate and confirmed objective response rate (ORR) were assessed by blinded independent central review (BICR) and investigator assessment. Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Confirmed ORR was defined as the number of participants with complete and partial responses and confirmed by a second assessment.

Time frame:
From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years
Reported as:
Count of participants · Participants
Best Overall Response and Confirmed Objective Response Rate (ORR) in Participants With HER2-low Breast Cancer (All Patients)
ParticipantsTrastuzumab Deruxtecan (T-DXd)Physician's Choice
BICR: Complete response132
BICR: Partial response18328
BICR: Stable disease12991
BICR: Progressive disease3141
BICR: Not evaluable1722
Investigator: Complete response60
Investigator: Partial response18731
Investigator: Stable disease13593
Investigator: Progressive disease3240
Investigator: Not evaluable1320
BICR: Confirmed Objective response rate19530
Investigator: Confirmed Objective response rate19331
SecondaryDuration of Response in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer

Duration of Response (DoR) is defined as the date of the first documented objective response (complete response \[CR\] or partial response \[PR\]) to the first documented disease progression or death, whichever occurs first. DoR was based on blinded independent central review (BICR) and investigator assessment. Median was from Kaplan-Meier estimate. Confidence interval for median was computed using the Brookmeyer-Crowley method.

Time frame:
From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years
Reported as:
Median · months
Duration of Response in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
monthsTrastuzumab Deruxtecan (T-DXd)Physician's Choice
BICR: DoR10.7 (8.5 to 13.7)6.8 (6.5 to 9.9)
Investigator: DoR8.3 (7.1 to 11.1)5.6 (3.6 to 6.8)
SecondaryDuration of Response in Participants With HER2-low Breast Cancer (All Patients)

Duration of Response (DoR) is defined as the date of the first documented objective response (complete response \[CR\] or partial response \[PR\]) to the first documented disease progression or death, whichever occurs first. DoR was based on blinded independent central review (BICR) and investigator assessment. Median was from Kaplan-Meier estimate. Confidence interval for median was computed using the Brookmeyer-Crowley method.

Time frame:
From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years
Reported as:
Median · months
Duration of Response in Participants With HER2-low Breast Cancer (All Patients)
monthsTrastuzumab Deruxtecan (T-DXd)Physician's Choice
BICR: DoR10.7 (8.5 to 13.2)6.8 (6.0 to 9.9)
Investigator: DoR8.3 (7.0 to 9.9)5.6 (3.7 to 6.6)
Other pre-specifiedAll-Cause Mortality

All-cause mortality is defined as all anticipated and unanticipated deaths due to any cause, with the number and frequency of such events by arm or comparison group of the clinical study.

Time frame:
From the date of randomization up to the date of death due to any cause, up to approximately 3 years
Reported as:
Count of participants · Participants
All-Cause Mortality
ParticipantsTrastuzumab Deruxtecan (T-DXd)Physician's Choice
All-Cause Mortality14888

Adverse events

Collected over Adverse events (AEs) were collected from the time of signing the main informed consent form up to 40 days (+7 days) after the last treatment, whether observed by the investigator or reported by the participant, up to approximately 3 years in the Safety Analysis Set.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab Deruxtecan (T-DXd)149/373 (39.9%)103/371 (27.8%)366/371 (98.7%)
Physician's Choice90/184 (48.9%)43/172 (25%)167/172 (97.1%)
Most frequent serious events
Showing 10 of 121
Most frequent serious events
EventTrastuzumab Deruxtecan (T-DXd)Physician's Choice
OverdoseInjury, poisoning and procedural complications0/3715/172
Febrile neutropeniaBlood and lymphatic system disorders4/3714/172
PneumoniaInfections and infestations7/3711/172
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders7/3710/172
PneumonitisRespiratory, thoracic and mediastinal disorders7/3710/172
Medication errorInjury, poisoning and procedural complications0/3713/172
SepsisInfections and infestations5/3710/172
DyspnoeaRespiratory, thoracic and mediastinal disorders5/3712/172
NeutropeniaBlood and lymphatic system disorders0/3712/172
ColitisGastrointestinal disorders0/3712/172
Most frequent other events
Showing 10 of 53
Most frequent other events
EventTrastuzumab Deruxtecan (T-DXd)Physician's Choice
NauseaGastrointestinal disorders281/37152/172
VomitingGastrointestinal disorders148/37123/172
AlopeciaSkin and subcutaneous tissue disorders147/37157/172
AnaemiaBlood and lymphatic system disorders137/37144/172
Neutrophil count decreasedInvestigations81/37161/172
ConstipationGastrointestinal disorders124/37138/172
Decreased appetiteMetabolism and nutrition disorders118/37133/172
FatigueGeneral disorders110/37149/172
White blood cell count decreasedInvestigations78/37149/172
DiarrhoeaGastrointestinal disorders100/37138/172

Baseline characteristics

Baseline characteristics were assessed in the Full Analysis Set. The Full Analysis Set included all participants randomized into the study, including those who did not receive a dose of study treatment. Participants were analyzed according to the treatments and strata assigned at randomization.

Age, Categorical
Age, Categorical(Participants)Trastuzumab Deruxtecan (T-DXd)Physician's ChoiceTotal
<=18 years000
Between 18 and 65 years290136426
>=65 years8348131
Age, Continuous
Age, Continuous(years)Trastuzumab Deruxtecan (T-DXd)Physician's ChoiceTotal
Mean56.5 ± 10.656.5 ± 11.556.5 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)Trastuzumab Deruxtecan (T-DXd)Physician's ChoiceTotal
Female371184555
Male202
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Trastuzumab Deruxtecan (T-DXd)Physician's ChoiceTotal
White17691267
Black or African American7310
Asian15172223
Native Hawaiian or other Pacific Islander101
Other381755
Missing011
08

Study locations

208 sites
  • Ironwood Cancer & Research Centers - Chandler II
    Chandler, Arizona 85224, United States
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
  • Cancer Treatment Centers of America at Western Regional Medical Center
    Goodyear, Arizona 85338, United States
  • UCLA School of Medicine
    Los Angeles, California 90095, United States
  • Stanford Cancer Institute
    Palo Alto, California 94305, United States
  • Cancer Care Associates Medical Group, Inc. TORI
    Redondo Beach, California 90277, United States
  • University of California at San Francisco (PARENT)
    San Francisco, California 94158, United States
  • Eastern Connecticut Hematology/Oncology Assoc.
    Norwich, Connecticut 06360, United States
  • Christiana Care Health Services, Inc.
    Newark, Delaware 19713, United States
  • Sylvester Comprehensive Cancer Center - Deerfield Beach
    Boca Raton, Florida 33426, United States
  • Florida Cancer Specialists (South Region)
    Fort Myers, Florida 33916, United States
  • Memorial Healthcare System MRH Cancer Center
    Hollywood, Florida 33021, United States
  • Orlando Health, Inc.
    Orlando, Florida 32806, United States
  • Moffitt Cancer Center -Tampa
    Tampa, Florida 33139, United States
  • Cancer Treatment Centers of America-Georgia
    Newnan, Georgia 30263, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Cancer Treatment Centers of America
    Zion, Illinois 60099, United States
  • Cancer Center of Kansas
    Wichita, Kansas 67214, United States
  • Touro Infirmary
    New Orleans, Louisiana 70115, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Saint Luke's Hospital of Kansas City
    Kansas City, Missouri 64111, United States
  • Saint Barnabas Medical Center
    Livingston, New Jersey 07039, United States
  • New York University Medical Center
    New York, New York 10016, United States
  • Memorial Sloan Kettering Hospital
    New York, New York 10065, United States
  • Weill Cornell Medicine Breast Center
    New York, New York 10065, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • University of Pittsburgh Medical Center Health System
    Pittsburgh, Pennsylvania 15219, United States
  • St Francis Hospital
    Greenville, South Carolina 29601, United States
  • Brig Center for Cancer Care and Survivorship
    Knoxville, Tennessee 37909, United States
  • Baptist Cancer Center
    Memphis, Tennessee 38120, United States
  • Tennessee Oncology - Skyline Satellite
    Nashville, Tennessee 37201, United States
  • BloomTrials Clinical Research, LLC
    Dallas, Texas 75234, United States
  • The Methodist Hospital Research Institute
    Houston, Texas 77030, United States
  • University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics
    Houston, Texas 77030, United States
  • Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
  • Medizinische Universität Innsbruck
    Innsbruck, 6020, Austria
  • Kepler Universitätsklinikum
    Linz, 4020, Austria
  • LKH - Universitätsklinikum der PMU Salzburg
    Salzburg, 5020, Austria
  • AKH - Medizinische Universität Wien (4305)
    Vienna, 1090, Austria
  • Klinikum Wels-Grieskirchen GmbH
    Wels, 4600, Austria
  • Institut Jules Bordet
    Brussels, 1000, Belgium
  • Universitair Ziekenhuis Brussel
    Brussels, 1090, Belgium
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Grand Hôpital de Charleroi
    Loverval, 6280, Belgium
  • CHU UCL Namur
    Namur, 5000, Belgium
  • Centre Hospitalier Wallonie picarde - Site IMC
    Tournai, 7500, Belgium
  • Tom Baker Cancer Center
    Calgary, Alberta T2N4N2, Canada
  • Toronto Sunnybrook Hospital
    Toronto, Ontario M4N 3M5, Canada
  • McGill University - Dept. Oncology Clinical Research Program
    Montreal, Quebec H2W 1S6, Canada
  • Anhui Provincial Hospital
    Hefei, Anhui 230001, China
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality 100021, China
  • Chinese PLA General Hospital
    Beijing, Beijing Municipality 100853, China
  • Fuzhou General Hospital of Nanjing Military Area Command of Chinese PLA
    Fuzhou, Fujian 350025, China
  • Sun Yat-sen Memorial hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510120, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150081, China
  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
  • The Affiliated Drum Tower Hospital of Nanjing University
    Nanjing, Jiangsu 210008, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130000, China
  • Jilin Cancer Hospital
    Changchun, Jilin 130012, China
  • Liaoning Cancer Hospital & Institute
    Shenyang, Liaoning 110042, China
  • General Hospital of Ningxia Medical University
    Yinchuan, Ningxia Hui 750004, China
  • Linyi Cancer Hospital
    Linyi, Shandong 276001, China
  • Shanghai General Hospital
    Shanghai, Shanghai Municipality 200080, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality 20032, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
    Hangzhou, Zhejiang 310016, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
  • Institut Paoli Calmettes
    Marseille, Bouches-du-Rhône 13009, France
  • Centre François Baclesse
    Caen, Calvados 14076, France
  • CARIO - Centre Armoricain de Radiothérapie, Imagerie médicale et Oncologie
    Plérin, Cotes d'Armor 22190, France
  • CHU Brest - Hôpital Morvan
    Brest, Finistere 29609, France
  • Institut Bergonié
    Bordeaux, Gironde 33076, France
  • Clinique Clementville
    Montpellier, Herault 34070, France
  • Institut Régional du Cancer de Montpellier
    Montpellier, Herault 34298, France
  • CRLCC Eugene Marquis
    Rennes, Ille Et Vilaine 35042, France
  • ICO - Site René Gauducheau
    Saint-Herblain, Loire Atlantique 44805, France
  • Centre Hospitalier Emile Roux
    Le Puy-en-Velay, Loiret 43012, France
  • ICO - Site Paul Papin
    Angers, Maine Et Loire 49055, France
  • Centre Hospitalier Valenciennes
    Valenciennes, Nord 59322, France
  • Hôpital Saint-Louis - Paris
    Paris, Paris 75475, France
  • Clinique Victor Hugo - Centre Jean Bernard
    Le Mans, Sarthe 72015, France
  • Institut Sainte Catherine
    Avignon, Vaculuse 84918, France
  • Hôpital d'Instruction des Armees Begin*
    Saint-Mandé, Val De Marne 94160, France
  • Institut Gustave Roussy
    Villejuif, Val De Marne 94805, France
  • Institut Curie - site de Paris
    Paris, 75005, France
  • Hopital Tenon
    Paris, 75020, France
  • Universitaetsklinikum Heidelberg
    Heidelberg, Baden-Wurttemberg 69120, Germany
  • Klinikum der Universitaet Muenchen - Campus Grosshardern
    Munich, Bavaria 81377, Germany
  • General Hospital of Athens "Alexandra"
    Athens, 11528, Greece
  • General Oncology Hospital of Kifissia " Agioi Anargyroi"
    Athens, 14564, Greece
  • Athens Medical Center
    Athens, 15125, Greece
  • University General Hospital of Heraklion
    Heraklion, 71110, Greece
  • University General Hospital of Larissa
    Larissa, 41110, Greece
  • Bioclinic Thessaloniki
    Thessaloniki, 54622, Greece
  • Euromedica General Clinic Thessaloniki
    Thessaloniki, 54645, Greece
  • General Hospital Papageorgiou
    Thessaloniki, 56429, Greece

Showing the first 100 of 208 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5. PubMed 35665782 ↗
  • Iyengar AR, Downs EP, Mehta S, Rangarajan N, Woo MS, Sredni ST, Donato RD, Simsek S, Wilson DM, Krieser K, Patzke EB, Kyek N, Anderson C, Wagner T, Hipp J, Nassar A, Barman H. HER2-Ultralow: Prevalence, Characteristics, and Treatment Choices Among Advanced Breast Cancer Patients With Tumors Initially Scored as IHC 0. Breast J. 2026;2026(1):e7212120. doi: 10.1155/tbj/7212120. PubMed 42340017 ↗
  • Modi S, Jacot W, Iwata H, Park YH, Vidal Losada M, Li W, Tsurutani J, Ueno NT, Zaman K, Prat A, Papazisis K, Rugo HS, Yamashita T, Harbeck N, Im SA, De Laurentiis M, Pierga JY, Wang X, Gombos A, Tokunaga E, Orbegoso Aguilar C, Yung L, Xiao F, Cheng Y, Cameron D. Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial. Nat Med. 2025 Dec;31(12):4205-4213. doi: 10.1038/s41591-025-03981-4. Epub 2025 Oct 8. PubMed 41062831 ↗
  • Ueno NT, Cottone F, Dunton K, Jacot W, Yamashita T, Sohn J, Tokunaga E, Prat A, Tsurutani J, Park YH, Rugo HS, Xu B, Cardoso F, Mitri Z, Mahtani R, Aguilar CO, Xiao F, Harbeck N, Cameron DA, Modi S. Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC. Oncologist. 2025 May 8;30(5):oyaf048. doi: 10.1093/oncolo/oyaf048. PubMed 40349139 ↗
  • Yamashita T, Sohn JH, Tokunaga E, Niikura N, Park YH, Lee KS, Chae YS, Xu B, Wang X, Im SA, Li W, Lu YS, Aguilar CO, Nishijima S, Nishiyama Y, Sugihara M, Modi S, Tsurutani J. Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study. Breast Cancer. 2024 Sep;31(5):858-868. doi: 10.1007/s12282-024-01600-7. Epub 2024 Jun 17. PubMed 38884900 ↗
  • Ma R, Shi Y, Yan R, Yin S, Bu H, Huang J. Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor receptor 2-low/positive advanced breast cancer:A meta-analysis of randomized controlled trials. Crit Rev Oncol Hematol. 2024 Apr;196:104305. doi: 10.1016/j.critrevonc.2024.104305. Epub 2024 Mar 3. PubMed 38442809 ↗
  • Jhaveri K, Eli LD, Wildiers H, Hurvitz SA, Guerrero-Zotano A, Unni N, Brufsky A, Park H, Waisman J, Yang ES, Spanggaard I, Reid S, Burkard ME, Vinayak S, Prat A, Arnedos M, Bidard FC, Loi S, Crown J, Bhave M, Piha-Paul SA, Suga JM, Chia S, Saura C, Garcia-Saenz JA, Gambardella V, de Miguel MJ, Gal-Yam EN, Rapael A, Stemmer SM, Ma C, Hanker AB, Ye D, Goldman JW, Bose R, Peterson L, Bell JSK, Frazier A, DiPrimeo D, Wong A, Arteaga CL, Solit DB. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Ann Oncol. 2023 Oct;34(10):885-898. doi: 10.1016/j.annonc.2023.08.003. Epub 2023 Aug 18. PubMed 37597578 ↗
  • Rugo HS, Crossno CL, Gesthalter YB, Kelley K, Moore HB, Rimawi MF, Westbrook KE, Buys SS. Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer. JCO Oncol Pract. 2023 Aug;19(8):539-546. doi: 10.1200/OP.22.00480. Epub 2023 May 19. PubMed 37207306 ↗
  • Narayan P, Dilawari A, Osgood C, Feng Z, Bloomquist E, Pierce WF, Jafri S, Kalavar S, Kondratovich M, Jha P, Ghosh S, Tang S, Pazdur R, Beaver JA, Amiri-Kordestani L. US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer. J Clin Oncol. 2023 Apr 10;41(11):2108-2116. doi: 10.1200/JCO.22.02447. Epub 2023 Feb 13. PubMed 36780610 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Jan 2022, 36 months.

Results were first posted in Jun 2023, 1 year 5 months after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 36 months is close to that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

Completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → May 2026, on Sep 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2018
First posted
Nov 7, 2018
StartActual
Dec 27, 2018
Primary completionActual
Jan 11, 2022
CompletionActual
May 19, 2026was Aug 2026
Results first posted
Jun 15, 2023
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Sep 28, 2026
Study completion
Aug 1, 2026→May 19, 2026 (actual)
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Active, not recruiting→Completed
    Study completion Aug 1, 2026→May 19, 2026 (now actual)
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03734029
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
Nov 7, 2018
Start date
Dec 27, 2018
Primary completion
Jan 11, 2022
Completion
May 19, 2026
Results posted
Jun 15, 2023
Last update
Sep 28, 2026

Study contacts

Global Clinical Leader
study director · Daiichi Sankyo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion